US 9,066,923 B2 · Methods for Alzheimer's disease treatment and cognitive enhancement

Abstract

The present invention relates to compositions comprising a combination of PKC activators and PKC inhibitors and methods to modulate α-secretase activity; improve or enhance cognitive ability; and/or reduce neurodegeneration in individuals suffering from diseases that impair cognitive ability, particularly Alzheimer's Disease. The invention also relates to methods for improving or enhancing cognitive ability. The present invention also provides methods for increasing the generation of non-amyloidogenic soluble APP (sAPP) comprising the activation of protein kinase C (PKC) in the brain and inhibiting PKC in peripheral tissues. Macrocyclic lactones (i.e. bryostatin class and neristatin class) are preferred PKC activators and Vitamin E is a preferred PKC inhibitor for use in the inventive composition.

Claims13

Dependent claims

A method for reducing neurodegeneration comprising administering to a subject in need thereof a composition comprising:

a) bryostatin-1;
b) vitamin E;
and
c) a pharmaceutically acceptable carrier,
wherein vitamin E is administered in a dose between 15 and 2,000 IU per day.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

12/538,245Filed 10 Aug 2009 · division

Priority

7 Mar 2002

Published

US 2010/0029744 A14 Feb 2010

Granted

30 Jun 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification18 codes

A61K 31/355
3,4-Dihydrobenzopyrans, e.g. chroman, catechin: tocopherols, e.g. vitamin E
A61K 31/00
Medicinal preparations containing organic active ingredients
A61K 31/365
Having oxygen as the only ring hetero atom, e.g. fungichromin: lactones
A61K 31/366
Lactones: having six-membered rings, e.g. delta-lactones

Family

Application60/362,080Us provisional application · filed 7 Mar 2002

Application10/167,491Parent of this continuation-in-part · filed 13 Jun 2002

Application10/937,509Parent of this division · filed 10 Sep 2004

US 6,825,229 B2Parent of this continuation-in-part · filed 30 Nov 2004

US 2010/0029744 A1Pre-grant publication · published 4 Feb 2010

Application10/937,509Parent of this continuation-in-part

US 2003/0171356 A1Published application

US 2005/0065205 A1Published application

US 9,066,923 B2This patent

From the US filing history. Foreign family members aren’t listed.

Methods for Alzheimer's disease treatment and cognitive enhancement

Life of this patent

Methods for Alzheimer's disease treatment and cognitive enhancement

Life of this patent

Abstract

Claims13